- $178.53m
- $59.64m
- $335.71m
- 62
- 68
- 84
- 83
Annual income statement for Inogen, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 308 | 358 | 377 | 316 | 336 |
Cost of Revenue | |||||
Gross Profit | 138 | 176 | 154 | 127 | 155 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Total Operating Expenses | 315 | 349 | 462 | 425 | 378 |
Operating Profit | -6.72 | 9.24 | -85.2 | -109 | -42.5 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -5.28 | 8.66 | -83.3 | -102 | -36.5 |
Provision for Income Taxes | |||||
Net Income After Taxes | -5.83 | -6.33 | -83.8 | -102 | -35.9 |
Net Income Before Extraordinary Items | |||||
Net Income | -5.83 | -6.33 | -83.8 | -102 | -35.9 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -5.83 | -6.33 | -83.8 | -102 | -35.9 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -0.417 | 0.054 | -1.74 | -3.14 | -1.41 |